非小细胞肺癌立体定向放疗后复发相关CT影像特征
本研究纳入59例经活检证实的非小细胞肺癌患者,分析SBRT后约3个月首次随访CT的34个语义特征和219个影像组学特征,采用Cox模型和Harrel C指数探索总生存、无复发生存和局部区域无复发生存的预测因子,三个模型五折交叉验证AUC均高于0.8。
要点
- SBRT后3个月首次随访CT影像特征可早期预测疾病进展。
- 血管受侵和淋巴结肿大与OS、RFS及LR-RFS均相关。
- 三个预后模型五折交叉验证AUC均高于0.8。
核心结论
- SBRT后3个月即可利用CT影像特征预测疾病进展,有助于临床决策。
研究设计与样本
- 研究纳入59例经活检证实的非小细胞肺癌患者,首次随访CT于SBRT后约3个月(中位91天)进行。
- 影像特征包括34个手动评分的语义特征和219个自动提取的影像组学特征。
- 采用Cox比例风险模型和Harrel C指数探索OS、RFS和LR-RFS的预测因子。
- 对最终预后模型进行五折交叉验证。
主要发现
- 中位随访时间为42个月。
- OS模型包含ECOG体力状态(HR=3.13,95%CI:1.17-8.41)、血管受侵(HR=3.21,95%CI:1.29-8.03)、淋巴结肿大(HR=3.59,95%CI:1.58-8.16)和影像组学特征第一主成分(HR=1.24,95%CI:1.02-1.51)。
- RFS模型包含血管受侵(HR=3.06,95%CI:1.40-6.70)、血管附着(HR=3.46,95%CI:1.65-7.25)、胸膜牵拉(HR=3.24,95%CI:1.41-7.42)、淋巴结肿大(HR=6.41,95%CI:2.58-15.90)和相对强化(HR=1.40,95%CI:1.00-1.96)。
- LR-RFS模型包含血管受侵(HR=4.96,95%CI:2.23-11.03)、淋巴结肿大(HR=2.64,95%CI:1.19-5.82)、圆形度(F13,HR=1.60,95%CI:1.10-2.32)和3D Laws特征(F92,HR=1.96,95%CI:1.35-2.83)。
- 三个模型五折交叉验证的AUC均高于0.8。
临床怎么用
- SBRT后约3个月首次随访CT的影像特征可用于早期识别高复发风险患者。
- 血管受侵、淋巴结肿大等语义特征和影像组学特征可辅助制定后续治疗决策。
局限性
- 样本量较小(59例),需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Predicting recurrence after stereotactic body radiotherapy (SBRT) in non-small cell lung cancer (NSCLC) patients is problematic, but critical for the decision of following treatment. This study aims to investigate the association of imaging features derived from the first follow-up computed tomography (CT) on lung cancer patient outcomes following SBRT, and identify patients at high risk of recurrence. METHODS: Fifty nine biopsy-proven non-small cell lung cancer patients were qualified for this study. The first follow-up CTs were performed about 3 months after SBRT (median time: 91 days). Imaging features included 34 manually scored radiological features (semantics) describing the lesion, lung and thorax and 219 quantitative imaging features (radiomics) extracted automatically after delineation of the lesion. Cox proportional hazard models and Harrel's C-index were used to explore predictors of overall survival (OS), recurrence-free survival (RFS), and loco-regional recurrence-free survival (LR-RFS). Five-fold cross validation was performed on the final prognostic model. RESULTS: The median follow-up time was 42 months. The model for OS contained Eastern Cooperative Oncology Group (ECOG) performance status (HR = 3.13, 95% CI: 1.17-8.41), vascular involvement (HR = 3.21, 95% CI: 1.29-8.03), lymphadenopathy (HR = 3.59, 95% CI: 1.58-8.16) and the 1st principle component of radiomic features (HR = 1.24, 95% CI: 1.02-1.51). The model for RFS contained vascular involvement (HR = 3.06, 95% CI: 1.40-6.70), vessel attachment (HR = 3.46, 95% CI: 1.65-7.25), pleural retraction (HR = 3.24, 95% CI: 1.41-7.42), lymphadenopathy (HR = 6.41, 95% CI: 2.58-15.90) and relative enhancement (HR = 1.40, 95% CI: 1.00-1.96). The model for LR-RFS contained vascular involvement (HR = 4.96, 95% CI: 2.23-11.03), lymphadenopathy (HR = 2.64, 95% CI: 1.19-5.82), circularity (F13, HR = 1.60, 95% CI: 1.10-2.32) and 3D Laws feature (F92, HR = 1.96, 95% CI: 1.35-2.83). Five-fold cross-validated the areas under the receiver operating characteristic curves (AUC) of these three models were all above 0.8. CONCLUSIONS: Our analysis reveals disease progression could be prognosticated as early as 3 months after SBRT using CT imaging features, and these features would be helpful in clinical decision-making.
引用
- Li Q, Kim J, Balagurunathan Y, et al. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy. Radiat Oncol. 2017. PMID: 28946909. doi:10.1186/s13014-017-0892-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。